Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients

AIMS: Cetuximab associated with cisplatin and 5‐fluorouracil is used to treat patients with inoperable or metastatic head and neck squamous cell carcinomas (HNSCC) up until disease progression or unacceptable toxicities. To date, no biomarkers of efficacy are available to select patients who will be...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Clin Pharmacol
Päätekijät: Le Louedec, Félicien, Alix‐Panabières, Catherine, Lafont, Thierry, Allal, Ben C., Garrel, Renaud, Digue, Laurence, Guigay, Joël, Cupissol, Didier, Delord, Jean‐Pierre, Lallemant, Benjamin, Alfonsi, Marc, Aubry, Karine, Mazel, Martine, Becher, François, Perriard, Françoise, Chatelut, Etienne, Thomas, Fabienne
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6533440/
https://ncbi.nlm.nih.gov/pubmed/30811063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13907
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia